The study, primarily authored by Dr. Foley, examines the efficacy and safety of Injectable Discogenic Cell Therapy.
Dr. Foley holds several professional appointments including director of complex spine surgery at Semmes-Murphey Neurologic and Spine Institute and professor of neurosurgery at the University of Tennessee Health Science Center, both in Memphis.
DiscGenics is a spine therapeutics company focused on stem cell and tissue engineering treatments for degenerative disc disease.
More Articles on Spine:
Mercy Medical Center – Des Moines Earns Blue Distinction
10 Statistics on Reoperation After Spine Surgery for Disc Herniation
Infection Rate Associated With Irradiated Allograft Bone
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
